Is Bliss GVS Pharma overvalued or undervalued?

3 hours ago

Share Via

As of December 4, 2025, Bliss GVS Pharma is fairly valued with a PE ratio of 16.35, outperforming the Sensex recently, while compared to peers, Sun Pharma is expensive at a PE of 37.78, and Aurobindo Pharma is also fairly valued at a PE of 20.77.

Valuation Metrics and Financial Health

Bliss GVS Pharma trades at a price-to-earnings (PE) ratio of approximately 16.35, which is moderate within the pharmaceutical sector. Its price-to-book value stands at 1.58, indicating the market values the company at nearly one and a half times its net asset value. The enterprise value to EBITDA ratio of 13.26 suggests a reasonable valuation relative to earnings before interest, tax, depreciation, and amortisation.

Importantly, the company’s PEG ratio is below 1 at 0.92, signalling that its price is not excessively high relative to its earnings growth potential. However, the dividend yield is modest at 0.29%, which may be less attractive to income-focused investors.

Return on capital employed (ROCE) and return on equity (ROE) hover around 9.3% and 9.7% respectively, reflecting moderate efficiency in generating profits from capital and shareholder equity. These returns, while respectable, are not exceptionally high, which partly explains the fair valuation grade.

Peer Comparison: Contextualising Bliss GVS Pharma

When compared with its pharmaceutical peers, Bliss GVS Pharma’s valuation appears balanced. Industry giants such as Sun Pharma Industries, Divi’s Laboratories, and Torrent Pharma are classified as expensive or very expensive, with PE ratios ranging from the high 30s to nearly 70 and EV/EBITDA multiples well above 20. This positions Bliss GVS Pharma as a more reasonably priced option within the sector.

Conversely, companies like Cipla, Dr Reddy’s Laboratories, Zydus Lifesciences, and Lupin are rated attractive, with slightly higher PE ratios but often lower EV/EBITDA multiples and varying PEG ratios. This suggests that while Bliss GVS Pharma is not the cheapest stock in the sector, it is also not overvalued relative to these peers.

Other mid-tier companies such as Aurobindo Pharma and Alkem Laboratories share a fair valuation status, with PE ratios and EV/EBITDA multiples somewhat comparable to Bliss GVS Pharma, reinforcing the notion that the company’s current market price is justified by its fundamentals.

Stock Price Performance and Market Sentiment

Bliss GVS Pharma’s stock price has shown resilience and moderate growth over recent periods. The current price of ₹169.55 is closer to its 52-week high of ₹190.65 than its low of ₹105.05, indicating a recovery and positive momentum. Over the past month, the stock has gained over 10%, outperforming the Sensex’s modest 2.16% rise in the same timeframe.

Year-to-date returns are positive but lag behind the broader market, while the three-year return of 130.05% significantly outpaces the Sensex’s 35.62%, highlighting strong medium-term performance. However, longer-term returns over five and ten years have been negative or subdued, reflecting challenges or market rotations in the pharmaceutical sector.

Conclusion: Fair Valuation Reflecting Balanced Prospects

Bliss GVS Pharma’s shift from an attractive to a fair valuation grade is a reflection of its current market standing. The company is neither undervalued nor overvalued but occupies a middle ground supported by solid financial ratios and reasonable growth expectations. Its valuation multiples are moderate compared to both expensive sector leaders and more attractively priced peers.

Investors seeking exposure to the pharmaceutical sector with a balanced risk-reward profile may find Bliss GVS Pharma a suitable candidate. However, those looking for higher growth or income might consider alternatives with stronger returns on capital or higher dividend yields. The stock’s recent price appreciation and positive momentum suggest confidence, but the modest ROCE and ROE caution against overenthusiasm.

Overall, Bliss GVS Pharma represents a fairly valued stock with steady fundamentals and competitive positioning, making it a prudent choice for investors favouring stability over aggressive growth in the pharmaceutical space.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)

MOJO SCORE